Amsterdam UMC Ventures

What Amsterdam UMC Ventures does

Amsterdam UMC Ventures Holding BV is an early-stage investment holding company founded in 1995 and wholly owned by Amsterdam University Medical Centers (Amsterdam UMC). It was established to commercialise academic research through spin-off companies while maintaining structural separation between public and private funds, with proceeds (dividends and exits) flowing back to Amsterdam UMC. The holding participates in spin-offs and provides governance, finance, management, and advisory services to portfolio companies, while also co-managing the combined portfolio of sibling holdings UvA Ventures Holding and HvA Ventures Holding under a single leadership team. The combined portfolio is classified into three categories: New Ventures, Contract Research, and Services; all Amsterdam UMC Ventures companies fall under New Ventures.

The underlying portfolio spans medical R&D, including RNA-based therapeutics (Phlox Therapeutics), AI-based elderly care monitoring (Kepler Vision Technologies — Kepler Night Nurse), AI-driven immunotherapy patient selection (Ellogon — EIDOS), biological pacemakers (PacingCure), cardiovascular and regenerative medicine, medical devices, diagnostics, and digital health. Amsterdam UMC Ventures does not develop its own products or charge end-customer pricing; instead, its revenue model is investment returns, supplemented by governance and management service fees. Deal flow originates primarily through IXA (Innovation Exchange Amsterdam), the joint technology transfer office, with co-investment from regional partners such as ROM InWest, ROM Utrecht Region, Innovatiefonds Noord-Holland, and the FIRST Fund. Customers in a strict sense are the academic researchers and portfolio companies it supports, alongside external investors seeking exposure to Amsterdam UMC's research pipeline.

Name

Amsterdam UMC Ventures

Legal name

Amsterdam UMC Ventures Holding BV

Website

https://amsterdamumcventures.nl

Company type

Private

Founded year

1995

Operating status

Operating

Short description

Amsterdam UMC Ventures Holding BV is a 1995-founded, wholly owned subsidiary of Amsterdam UMC that invests in and supports academic spin-off companies across therapeutics, AI, medical devices, and digital health, sharing management with UvA and HvA Ventures holdings.

Ownership category

akta.pro rank

Product category

University Venture Capital / Academic Spin-off Investment Holding

NAICS

Management of Companies and Enterprises (551), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Non-Operating Establishments (9995)

akta.pro industry

PRIMARYFSANAHAA

Strategic / Balance-Sheet CVC (On-balance-sheet investing)

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

SECONDARYFSANAHAI

Corporate Innovation & Technology Scouting Units (with investment mandate)

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

SECONDARYFSANAHAF

Corporate Strategic Partnership & Ecosystem Investment Arms

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

Keywords

• Academic spin-off investment
• Venture capital holdings
• Research commercialization
• University venture management
• Startup incubation services

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Investment returns (dividends and exits): Amsterdam UMC Ventures generates returns via dividends or exits from its portfolio companies (spin-offs). The company participates in spin-offs to create economic and societal value from research and education at Amsterdam UMC, with proceeds flowing back to Amsterdam UMC.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Amsterdam UMC Ventures Holding BV is an early-stage investment holding company that participates in academic spin-off companies originating from Amsterdam University Medical Centers (Amsterdam UMC). It provides portfolio companies with governance, finance and control, management, and advisory services, while segregating public funding from private revenue streams. It also co-manages spin-off portfolios from the University of Amsterdam (UvA) and the Hogeschool van Amsterdam (HvA) under a unified three-category structure: New Ventures, Contract Research, and Services.

Product overview

Amsterdam UMC Ventures Holding BV is an early-stage venture capital and holding company established in 1995 as a 100% subsidiary of Amsterdam University Medical Centers. It does not itself develop or sell products; rather, it holds equity stakes in and provides governance, finance, management, and advisory services to spin-off companies from Amsterdam UMC. The combined portfolio of Amsterdam UMC Ventures Holding, UvA Ventures Holding, and HvA Ventures Holding spans three categories: New Ventures, Contract Research, and Services. All Amsterdam UMC Ventures portfolio companies are classified under 'New Ventures.' Notable portfolio companies include Phlox Therapeutics (RNA therapies for genetic cardiomyopathies), Kepler Vision Technologies (AI computer vision for elderly care via the Kepler Night Nurse), and Ellogon (AI for immunotherapy patient selection via EIDOSTM). Supporting initiatives include ACE Incubator and StudiJob (student recruitment).

Differentiator

Problem solved

Functional benefit

Products and services

• StudiJob Uitzendbureau BV

Quantifiable outcome

• Phlox Therapeutics raised €1.9M in November 2024 to develop RNA therapies for genetic laminopathies
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• UvA Ventures Holding BVcoreStrategic or Co-development PartnerUvA Ventures Holding BV is a related holding company that manages spin-offs from the University of Amsterdam. Amsterdam UMC Ventures manages the combined portfolio alongside UvA Ventures and HvA Ventures, classifying ventures into three categories: New Ventures, Contract Research, and Services. Both holdings are operated by the same leadership team.
• HvA Ventures Holding BVcoreStrategic or Co-development PartnerHvA Ventures Holding BV manages spin-offs from the Hogeschool van Amsterdam (Amsterdam University of Applied Sciences). Amsterdam UMC Ventures co-manages the combined portfolio with UvA Ventures and HvA Ventures holdings.
• IXA (Innovation Exchange Amsterdam)coreStrategic or Co-development PartnerIXA is the technology transfer office of Amsterdam UMC and UvA responsible for commercialising scientific knowledge. IXA advises on valorisation routes, handles patent filing, negotiates licensing and research collaboration contracts, and provides proof-of-concept funding in collaboration with Amsterdam UMC Ventures.
• ACE IncubatorcoreStrategic or Co-development PartnerACE (Amsterdam Center for Entrepreneurship) is the academic startup incubator of the Amsterdam knowledge institutions. It offers startup programs to learn vital skills for starting a company. Amsterdam UMC Ventures supports startups through ACE Incubator and StudiJob. The incubator was ranked #1 in the Netherlands by Emerce in 2018.
• Startup VillageminorStrategic or Co-development PartnerStartup Village is a startup campus at Amsterdam Science Park developed by UvA Ventures to provide affordable office space to startups. Amsterdam UMC Ventures sponsors the Sharktank at Startup Village, an event space for startups to pitch to potential investors.
• Hubrecht InstituteminorStrategic or Co-development PartnerThe Hubrecht Institute is in a public-private partnership with Phlox Therapeutics, supported by Health~Holland, to deepen scientific understanding of cardiomyopathies and advance preclinical work.
• Dutch CardioVascular Alliance (DCVA)minorStrategic or Co-development PartnerDCVA, together with Regenerative Medicine Crossing Borders (RegMed XB), founded the FIRST Fund which invests alongside Amsterdam UMC Ventures in early-stage cardiovascular startups.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Erasmus MC Holdings: Another Dutch university medical center with investment/holding activities around its spin-offs, directly comparable in mission (medical academic commercialisation) though serving a different regional research ecosystem.
• UMC Utrecht Holdings: Dutch UMC with its own spin-off investment activities, including co-investment activity through Utrecht Health Seed Fund alongside Amsterdam UMC Ventures in Phlox Therapeutics.

Direct peers

• Oxford University Innovation: Oxford University's technology transfer and venture creation office, responsible for IP commercialisation, spin-out formation, and investment in academic ventures—directly comparable to Amsterdam UMC Ventures' function.
• BioGeneration Ventures (BGV): Dutch early-stage life sciences VC that manages the FIRST Fund and co-invests in Amsterdam UMC Ventures' portfolio companies, acting as a complementary specialized VC in the same Dutch biotech ecosystem.
• Karolinska Institutet Innovations: Innovation office of Sweden's leading medical university, investing in life sciences and healthcare spin-offs—comparable to Amsterdam UMC Ventures' medical-research focus.
• UvA Ventures Holding: Direct sister organization that manages spin-offs from the University of Amsterdam, operated by the same leadership team and sharing the combined portfolio alongside Amsterdam UMC Ventures.
• HvA Ventures Holding: Sister holding company for spin-offs from the Hogeschool van Amsterdam (University of Applied Sciences), co-managed with Amsterdam UMC Ventures under the same general director.
• Imperial College Innovations: Imperial College London's technology transfer office that creates and invests in academic spin-outs, with a similar portfolio profile in life sciences, medtech, and deep tech.
• Cambridge Enterprise: University of Cambridge's technology transfer and investment arm, providing governance, funding, and commercialisation support to academic spin-offs—analogous role to Amsterdam UMC Ventures within a top-tier European research institution.
• Innovatiefonds Noord-Holland: Regional Dutch innovation fund that co-invests in Amsterdam UMC/UvA spin-offs (e.g., SolarFoil, AMI, PacingCure), functioning as a peer regional CVC in the same ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/uva---amc-ventures---hva-holding-bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amsterdam UMC Ventures